Edgewise Therapeutics Inc (EWTX) Reports First Quarter 2024 Financial Results

GuruFocus Research
3 min read

In This Article:

  • Revenue: Reported revenue of $0.00 million, meeting the estimated revenue of $0.00 million.

  • Net Loss: Recorded a net loss of $28.5 million, which was above the estimated net loss of $31.52 million.

  • Earnings Per Share (EPS): Reported EPS of -$0.33, surpassing the estimated EPS of -$0.39.

  • Research and Development Expenses: R&D expenses remained steady at $27.7 million compared to the previous quarter.

  • General and Administrative Expenses: G&A expenses increased to $7.1 million from $6.2 million in the previous quarter.

  • Cash Position: Cash, cash equivalents, and marketable securities stood at $532.8 million as of March 31, 2024, a significant increase from $318.4 million at the end of the previous year.

On May 9, 2024, Edgewise Therapeutics Inc (NASDAQ:EWTX), a pioneering biopharmaceutical company specializing in muscle disease treatments, disclosed its financial outcomes for the first quarter of 2024 through an 8-K filing. The company, known for its innovative approach in developing therapies for severe, rare muscle disorders, highlighted significant clinical advancements alongside its financial results.

Company Overview

Edgewise Therapeutics Inc is at the forefront of addressing unmet medical needs in musculoskeletal diseases through the development of orally bioavailable, small molecule therapies. Their focus remains on debilitating diseases such as Becker and Duchenne muscular dystrophies.

Quarterly Financial Performance

For Q1 2024, Edgewise reported a net loss of $28.5 million, or $0.33 per share, which shows an improvement from the $30.1 million, or $0.47 per share, recorded in the previous quarter. This performance aligns closely with analyst expectations, which anticipated a loss of $0.39 per share and a net income loss of $31.52 million. The company's research and development expenses remained stable at $27.7 million, reflecting ongoing investments in their clinical programs.

Clinical Program Highlights and Achievements

The quarter was marked by significant progress in Edgewise's clinical trials, particularly with their lead candidate, sevasemten, which is being developed for multiple muscular dystrophies. Notable achievements include:

  • Positive two-year topline results from the ARCH trial in Becker Muscular Dystrophy, showing that sevasemten was well-tolerated and led to stabilization of North Star Ambulatory Assessment (NSAA) scores.

  • Advancement of the GRAND CANYON trial, a pivotal study which could potentially support a marketing application.

  • Initiation of the CIRRUS-HCM trial for EDG-7500, aimed at treating patients with obstructive hypertrophic cardiomyopathy (HCM).

Recommended Stories